/PRNewswire/ Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp.
Melbourne, Australia; 10 August 2022: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has signed a new DEP ® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new agreement follows an earlier DEP ® Antibody Drug Conjugate (ADC) agreement signed with MSD in February 2021.